Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22119678 | 0.98 | ALOX15 (0.55) | ALOX15KMT2AMEN1CYP2C19ALDH1A1 | |
| SCHEMBL1098265 | 0.86 | KEAP1 (0.50) | ALOX15KMT2AMEN1ACE2SIGMAR1 | |
| SCHEMBL11269259 | 0.84 | KEAP1 (0.43) | ALOX15KMT2AMEN1ACE2SIGMAR1 | |
| SCHEMBL19627823 | 0.79 | KMT2A (0.41) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL12551015 | 0.79 | ACE2 (0.67) | ALOX15KMT2AMEN1ALDH1A1ACE2 | |
| SCHEMBL21670132 | 0.78 | HPGD (0.35) | ALOX15KMT2AMEN1ALDH1A1KEAP1 | |
| SCHEMBL22779960 | 0.78 | ALOX15 (0.33) | ALOX15KMT2AMEN1 | |
| SCHEMBL1099307 | 0.77 | KMT2A (0.39) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL178300 | 0.77 | KMT2A (0.44) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL23226887 | 0.75 | ALDH1A1 (0.39) | KMT2AMEN1CYP2C19ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | claimed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | claimed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4638428-A1 | HETEROCYCLIC ACRYLIC ACID DERIVATIVES AS MONOMERS FOR THE SYNTHESIS OF POLYMERS FOR USE IN ION EXCHANGE ARTICLES | Solventum Intellectual Properties Company (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025105486-A1 | ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE | 第一三共株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-119219640-A | Nitrogen-containing ternary condensed ring derivative and application thereof | 杭州百新生物医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-12-26 | — | — | US | disclosed |
| US-5389647-A | A prodrugs as hypotensive agents, treating congestive heart failure, urogenital disorders, vision defects | ABBOTT LABORATORIES (US) | 1995-02-14 | — | — | US | disclosed |
| US-5244910-A | Treating hypertension, congestive heart failure | ABBOTT LABORATORIES (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0543936-A4 | RENIN INHIBITORS | — | 1993-06-30 | — | — | EP | disclosed |
| EP-0543936-A1 | RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992003429-A1 | RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1992-03-05 | — | — | WO | disclosed |
| US-4006239-A | Benzoic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
| US-3995044-A | Pyridine carboxylic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | ALOX15 4137/4885KMT2A 4363/4885MEN1 3002/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | ALOX15 1466/4885KMT2A 4793/4885MEN1 3067/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | ALOX15 1805/4885KMT2A 1474/4885MEN1 3745/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | ALOX15 3881/4885KMT2A 637/4885MEN1 3039/4885 |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, SNRPA, RNASE1 | ALOX15 2873/4885KMT2A 4081/4885MEN1 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.